QC
PACB icon

Quadrature Capital’s Pacific Biosciences PACB Stock Holding History

Quadrature Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149K Sell
112,503
-93,907
-45% -$168K ﹤0.01% 1174
2025
Q4 		$386K Sell
206,410
-145,945
-41% -$280K ﹤0.01% 764
2025
Q3 		$449K Buy
+352,355
New +$477K 0.01% 555

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quadrature Capital's PACB Position: Q1 2026 in Review

Quadrature Capital reduced its Pacific Biosciences (PACB) stake by 45% in Q1 2026, selling an estimated $168K and leaving 112,503 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #1174.

Quadrature Capital first reported a position in PACB in Q3 2025 and has held it in 3 quarters since. The position peaked at $449K in Q3 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Quadrature Capital held 112,503 shares of Pacific Biosciences worth $149K as of Q1 2026.
  • Quadrature Capital sold 93,907 Pacific Biosciences shares in Q1 2026, an estimated $168K.
  • Pacific Biosciences made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1174 holding.
  • Quadrature Capital first reported a position in Pacific Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Pacific Biosciences position peaked at $449K in Q3 2025.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.